Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Both treatments mimic certain gut hormones to tamp down a person's appetite and regulate their blood sugar. The popularity of those injectable drugs has forced both Eli Lilly and its rival Novo ...

Eli Lilly reported mixed results for the fourth ... Both treatments mimic certain gut hormones to tamp down a person's appetite and regulate their blood sugar. This story is developing.